Cataract surgery cost utility revisited in 2012: a new economic paradigm.

[1]  Clifford Goodman,et al.  American Society of Anesthesiologists , 2020, Definitions.

[2]  A S Detsky,et al.  How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[3]  D K Owens,et al.  Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. , 1995, JAMA.

[4]  A. Sommer,et al.  Cataract Surgery in One Eye or Both: A Billion Dollar per Year Issue , 1995 .

[5]  M C Weinstein,et al.  Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. , 1996, JAMA.

[6]  Milton C. Weinstein,et al.  Recommendations for Reporting Cost-effectiveness Analyses , 1996 .

[7]  M. Espallargues,et al.  Visual outcomes of cataract surgery in the United States, Canada, Denmark, and Spain. Report From the International Cataract Surgery Outcomes Study. , 1998, Archives of ophthalmology.

[8]  G. Brown,et al.  Vision and quality-of-life. , 1999, Transactions of the American Ophthalmological Society.

[9]  G. Brown,et al.  Difference between ophthalmologists' and patients' perceptions of quality of life associated with age-related macular degeneration. , 2000, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[10]  H R Rubin,et al.  Cost-utility analysis of the cochlear implant in children. , 2000, JAMA.

[11]  A. Cruess,et al.  Reliability of the time trade-off technique of utility assessment in patients with retinal disease. , 2001, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[12]  G. Brown,et al.  Quality of life associated with unilateral and bilateral good vision. , 2001, Ophthalmology.

[13]  Gary C. Brown,et al.  Utility values associated with blindness in an adult population , 2001, The British journal of ophthalmology.

[14]  Gary C. Brown,et al.  Incremental cost-effectiveness of initial cataract surgery. , 2002, Ophthalmology.

[15]  W. Nordhaus,et al.  The Health of Nations: The Contribution of Improved Health to Living Standards , 2002 .

[16]  Gary C. Brown,et al.  Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration. , 2002, Archives of ophthalmology.

[17]  G. Brown,et al.  Validity of the time trade-off and standard gamble methods of utility assessment in retinal patients , 2002, The British journal of ophthalmology.

[18]  Gary C. Brown,et al.  Quality of life associated with visual loss: a time tradeoff utility analysis comparison with medical health states. , 2003, Ophthalmology.

[19]  G. Brown,et al.  Quality of life with macular degeneration: perceptions of patients, clinicians, and community members , 2003, The British journal of ophthalmology.

[20]  G. Brown,et al.  Utilities associated with diabetic retinopathy: results from a Canadian sample , 2003, The British journal of ophthalmology.

[21]  Gary C. Brown,et al.  Cost-utility analysis of cataract surgery in the second eye. , 2003, Ophthalmology.

[22]  Gary C. Brown,et al.  Health care economic analyses and value-based medicine. , 2003, Survey of ophthalmology.

[23]  Gary C. Brown,et al.  Evidence-Based To Value-based Medicine , 2005 .

[24]  J. Schmier,et al.  IMPACT OF VISUAL IMPAIRMENT ON USE OF CAREGIVING BY INDIVIDUALS WITH AGE-RELATED MACULAR DEGENERATION , 2006, Retina.

[25]  Lauren M. Mercincavage,et al.  Expanded HIV Screening in the United States: Effect on Clinical Outcomes, HIV Transmission, and Costs , 2006, Annals of Internal Medicine.

[26]  Gary C. Brown,et al.  A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration. , 2007, Ophthalmology.

[27]  Richard J Willke,et al.  Association between vision loss and higher medical care costs in Medicare beneficiaries costs are greater for those with progressive vision loss. , 2007, Ophthalmology.

[28]  Gary C. Brown,et al.  A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration. , 2008, Ophthalmology.

[29]  G. Brown,et al.  The effect of comorbidities upon ocular and systemic health-related quality of life , 2008, British Journal of Ophthalmology.

[30]  E. Arias.  United States life tables, 2007. , 2011, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[31]  M. Tonelli,et al.  Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk , 2011, Canadian Medical Association Journal.

[32]  M. Brault.  Americans with Disabilities: 2010 , 2012 .

[33]  Daniel,et al.  Corresp ondence e 18 Re : Brown et al . : Cataract surgery cost utility revisited in 2012 : a new economic paradigm , 2022 .